Shenzhen Orli Biopharmaceutical Technology

Shenzhen Orli Biopharmaceutical Technology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of innovative small molecule therapeutics for oncology and other serious diseases. The company's pipeline is highlighted by VB15010, a potent and selective PARP-1 inhibitor currently being evaluated in Phase 1/2 trials for advanced solid tumors. Additionally, the company is advancing QLC1401 in combination therapies for ER+/HER2- breast cancer and exploring treatments for ischemic and neurodegenerative conditions. Shenzhen Orli leverages its expertise in medicinal chemistry and translational medicine to address significant unmet medical needs in the global healthcare market.